
Feature|Articles|July 6, 2026
FDA decisions in eye care: A first-half 2026 recap
Author(s)Abigail Lewis, Content Intern
Fact checked by: Jordana Joy, Editor
A summary of major FDA approvals and CRLs in eye care from the first half of 2026.
Advertisement
Advertisement
The first half of 2026 has delivered a notable mix of FDA approvals, complete response letters, and regulatory milestones across several therapeutic areas relevant to optometric practice. From first-in-class presbyopia drops and EDOF contact lenses to new tools for thyroid eye disease and ongoing setbacks in dry eye, the regulatory landscape has moved quickly. Below is a summary of the major decisions optometrists should be aware of heading into the second half of the year.
Related to this article

Yuvezzi’s Health Canada submission leads this week’s recap, plus AI front desks, the EMERALD trial, and Alberta’s scope expansion.

The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.

Nicole Haessly, OD, FAAO, discusses common unsafe contact lens habits, overlooked care steps, and how lens innovations have improved safety.

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

The school will be admitting its inaugural Doctor of Optometry class in summer 2027, with full accreditation possible in 2030-31.
Advertisement
Advertisement


